67617-98-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(2,5-DIMETHOXYPHENYL)-2-THIOUREA is used as a potential anti-cancer agent for its possible ability to target and inhibit the growth of cancer cells. 1-(2,5-DIMETHOXYPHENYL)-2-THIOUREA's specific mechanism of action and its effectiveness against various types of cancer are areas of ongoing research.
Used in Anti-inflammatory Applications:
As a potential anti-inflammatory agent, 1-(2,5-DIMETHOXYPHENYL)-2-THIOUREA may be utilized to reduce inflammation and associated symptoms in various conditions. 1-(2,5-DIMETHOXYPHENYL)-2-THIOUREA's impact on inflammatory pathways and its safety profile in this context are subjects of investigation.
Used in Diabetes Treatment:
1-(2,5-DIMETHOXYPHENYL)-2-THIOUREA is being studied for its potential role in diabetes management, possibly through its effects on glucose metabolism or insulin sensitivity. The exact mechanisms and clinical viability of this application are under exploration.
Used as an Antioxidant:
1-(2,5-DIMETHOXYPHENYL)-2-THIOUREA's potential as an antioxidant suggests its use in protecting cells from oxidative stress, which is implicated in numerous diseases and aging processes. Research is being conducted to determine the compound's efficacy and safety as an antioxidant in various settings.
Further research is necessary to understand the full scope of 1-(2,5-DIMETHOXYPHENYL)-2-THIOUREA's applications and to develop methods for its effective and safe use in medical and scientific fields.

InChI:InChI=1/C9H12N2O2S/c1-12-6-3-4-8(13-2)7(5-6)11-9(10)14/h3-5H,1-2H3,(H3,10,11,14)

Upstream product

• 40532-06-7 2-isothiocyanato-1,4-dimethoxybenzene 
• 1147550-11-5 ammonium thiocyanate 
• 102-56-7 2,5-dimethoxyaniline 
• 62994-90-5 2,5-Dimethoxybenzylamin*HCl 
• 2100-42-7 2-chloro-1,4-dimethoxybenzene 
• 67617-97-4 N-(2,5-dimethoxyphenyl)-N'-benzoylthiocarbamide 
• 75-15-0 carbon disulfide 

Downstream Products

• 158632-88-3 (4,5-dihydro-thiazol-2-yl)-(2,5-dimethoxy-phenyl)-amine 
• 1030631-30-1 C₂₂H₁₉ClN₄O₃S₂ 
• 333746-83-1 C₁₅H₁₆N₄O₂S₂ 
• 429621-26-1 N-(2,5-dimethoxyphenyl)-4-(4-methoxyphenyl)thiazol-2-amine 
• 1391724-80-3 C₁₇H₁₇FN₂O₄S₂ 
• 1391724-79-0 C₁₇H₁₆Cl₂N₂O₄S₂ 
• 1391724-78-9 C₁₇H₁₈N₂O₄S₂ 
• 1391724-77-8 C₂₁H₂₀N₂O₄S₂ 
• 1391724-76-7 C₁₇H₁₇N₃O₆S₂ 
• 1391724-75-6 C₁₇H₁₇N₃O₆S₂ 
• 1391724-74-5 C₂₆H₃₆N₂O₄S₂ 
• 1391724-73-4 C₁₅H₁₆N₂O₄S₃ 
• 1391724-71-2 C₁₈H₂₀N₂O₅S₂ 
• 1391724-70-1 C₂₁H₂₀N₂O₄S₂ 

Relevant academic research and scientific papers

Synthesis, SAR and docking studies of substituted aryl phenylthiazolyl phenylcarboxamide as potential protein tyrosine phosphatase 1B (PTP1B) inhibitors

In our continued effort to discover novel PTP1B inhibitor with improved in vivo activity, we attempted to optimize our previously discovered lead compound by replacing the sulfonyl group with benzoyl group to yield compound II. Additional structural modif

Design, synthesis and biological evaluation of novel semicarbazone-selenochroman-4-ones hybrids as potent antifungal agents

A series of novel 2,3-dihydro-4H-1-benzoselenin-4-one (thio)semicarbazone derivatives were designed and synthesized by using molecular hybridization approach. All the target compounds were characterized by HRMS and NMR and evaluated in vitro antifungal activity against five pathogenic strains. In comparison with precursor selenochroman-4-ones, the hybrid molecules in this study showed significant improvement in antifungal activities. Notably, compound B8 showed significant antifungal activity against other strains excluding Aspergillus fumigatus (0.25 μg/mL on Candida albicans, 2 μg/mL on Cryptococcus neoformans, 8 μg/mL on Candida zeylanoides and 2 μg/mL on fluconazole-sensitive strains of Candida albicans). Moreover, compounds B8, B9 and C2 also displayed most potent activities against four fluconazole-resistance strains. Especially the MIC values of the hybrid molecule B8 against fluconazole-resistant strains were in the range of 0.5–2 μg/mL. Therefore, the molecular hybridization approach in this study provided new ideas for the development of antifungal drug.

Structure-activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis

A series of 2-aminothiazoles was synthesized based on a HTS scaffold from a whole-cell screen against Mycobacterium tuberculosis (Mtb). The SAR shows the central thiazole moiety and the 2-pyridyl moiety at C-4 of the thiazole are intolerant to modification. However, the N-2 position of the aminothiazole exhibits high flexibility and we successfully improved the antitubercular activity of the initial hit by more than 128-fold through introduction of substituted benzoyl groups at this position. N-(3-Chlorobenzoyl)-4-(2-pyridinyl) -1,3-thiazol-2-amine (55) emerged as one of the most promising analogues with a MIC of 0.024 μM or 0.008 μg/mL in 7H9 media and therapeutic index of nearly ～300. However, 55 is rapidly metabolized by human liver microsomes (t1/2 = 28 min) with metabolism occurring at the invariant aminothiazole moiety and Mtb develops spontaneous low-level resistance with a frequency of ～10-5.

Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H37RV

In search of potential therapeutics for tuberculosis, we describe herein synthesis and biological evaluation of some substituted 4-arylthiazol-2-amino derivatives as modified analogues of the antiprotozoal drug Nitazoxanide (NTZ), which has recently been reported as potent inhibitor of Mtb H37Rv (Mtb MIC = 52.12 μM) with an excellent ability to evade resistance. Among the synthesized derivatives, the two compounds 7a (MIC = 15.28 μM) and 7c (MIC = 17.03 μM) have exhibited about three times better Mtb growth inhibitory activity over NTZ and are free from any cytotoxicity (Vero CC50 of 244 and 300 μM respectively). These two compounds represent promising leads for further optimization.

4′-Methyl-4,5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processing

The synthesis and ΔF508-CFTR corrector activity of a 148-member methylbithiazole-based library are reported. Synthetic routes were devised and optimized to generate methylbithiazole analogs in four steps. Corrector potency and efficacy were assayed using epithelial cells expressing human ΔF508-CFTR. These structure-activity data establish that the bithiazole substructure plays a critical function; eight novel methylbithiazole correctors were identified with low micromolar potencies.

Synthesis and QSAR studies in 2-(N-aryl-N-aroyl)amino-4,5-dihydrothiazole derivatives as potential antithrombotic agents

A series of 2-(N-aryl-N-aroyl)amino-4,5-dihydrothiazole derivatives have been synthesized via cyclocondensation of N-aryl thioureas with 2-bromoethylamine hydrobromide followed by the reaction of the product thus obtained with aroyl chlorides. Title compounds were evaluated for their antithrombotic activity in vivo in mice where one of these compound 29 provided 65% protection as compared to 77% protection offered by the standard Indomethacin. Quantitative Structure-Activity Relationship (QSAR) studies were performed on these compounds using physicochemical (hydrophobic, electronic, steric) parameter as independent and antithrombic activity as dependent parameter, where antithrombotic activity correlated best (r > 0.8) with electronic parameters (F, σ or μ) having high statistical significance > 99.9% (F2,22 > 15.0; F2,22α:0.001 = 11.0) suggesting that hydrophobic, steric and resonance factors are insignificant in this set of molecules for the activity.

Synthesis of thiophene-2-carboxamidines containing 2-aminothiazoles and their biological evaluation as urokinase inhibitors

The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino-1,3-thiazolyl]-thiophene-2-carboxamidines is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities.